{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T05:37:05Z","timestamp":1784871425210,"version":"3.55.0"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background.<\/jats:title>\n                    <jats:p>Mild histologic lesions of tubulo-interstitial inflammation could represent a \u201cresponse-to-wounding\u201d rather than allorecognition. Tissue gene expression may complement histopathology for T-cell-mediated rejection (TCMR) diagnostics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>We report on the incorporation of tissue gene expression testing using a Molecular Microscope Diagnostic System into the management of kidney transplant biopsies with suspected TCMR. Patients (N\u2005=\u2005209) were divided into 3 groups based upon diagnosis and TCMR therapy (with high-dose steroids and\/or anti-thymocyte globulin): Group 1: Untreated histologic TCMR with molecular quiescence (H+M\u2013); Group 2: Treated histologic and molecular TCMR (H+M+); and Group 3: Controls, with no histologic or molecular (H\u2013M\u2013) rejection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>\n                      At biopsy, estimated glomerular filtration rate was worse (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.006) in H+M+\u2005(N\u2005=\u200535; 33\u2005\u00b1\u200522\u2009mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      ) and H+M\u2013 (N\u2005=\u200530; 40\u2005\u00b1\u200518\u2009mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      ) groups; compared with H\u2013M\u2013 (N\u2005=\u2005144; 47\u2005\u00b1\u200524\u2009mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      ) group. In H+M\u2013 biopsies, mean molecular acute kidney injury scores (0.33 versus 0.10;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.03) were higher than in H\u2013M\u2013; while molecular TCMR was lower compared with H+M+\u2005(0.04 versus 0.54;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). At 12 m postbiopsy estimated glomerular filtration rate remained low (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) in H+M+\u2005(38\u2005\u00b1\u200522\u2009mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      ) but improved in untreated H+M\u2013 (44\u2005\u00b1\u200522\u2009mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      ) and H\u2013M\u2013 (50\u2005\u00b1\u200523\u2009mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      ) groups. At a mean follow-up of 2.1\u2005\u00b1\u20051.2 y post-index biopsy, death-censored graft survival was lower in H+M+\u2005(74%) than in H+M\u2013 (90%) and H\u2013M\u2013 (92%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.001). H+M+ cases had numerically higher rejection on follow-up biopsy (20%) than H+M\u2013 (7%) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.12) and de novo donor-specific antibody formation (H+M+\u200524%; H+M\u2013 10%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.13).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.<\/jats:title>\n                    <jats:p>In this large single-center study, biopsies with untreated histological TCMR and molecular quiescence had comparable clinical outcomes to cases with no rejection, whereas those with histologic and tissue gene expression confirmed TCMR had inferior outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/tp.0000000000005296","type":"journal-article","created":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:32Z","timestamp":1734912032000},"page":"1402-1412","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Tissue-based Gene Expression Diagnosis of Mild and Moderate T-cell-mediated Rejection to Guide Therapy in Kidney Transplants"],"prefix":"10.1097","volume":"109","author":[{"given":"Dhiren","family":"Kumar","sequence":"first","affiliation":[{"name":"Division of Nephrology, Virginia Commonwealth University, Richmond, VA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nihar","family":"Raju","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Virginia Commonwealth University, Richmond, VA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bekir","family":"Tanriover","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of Arizona, Tucson, AZ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louiza","family":"Azzouz","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Virginia Commonwealth University, Richmond, VA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irfan","family":"Moinuddin","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Virginia Commonwealth University, Richmond, VA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Philogene","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Virginia Commonwealth University, Richmond, VA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Layla","family":"Kamal","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Virginia Commonwealth University, Richmond, VA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felecia","family":"McDougan","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Virginia Commonwealth University, Richmond, VA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh Davis","family":"Massey","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Virginia Commonwealth University, Richmond, VA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selvaraj","family":"Muthusamy","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Virginia Commonwealth University, Richmond, VA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inkoo","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Virginia Commonwealth University, Richmond, VA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Halloran","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of Arizona, Tucson, AZ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Gupta","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Virginia Commonwealth University, Richmond, VA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,12,23]]},"reference":[{"key":"R1-20251023","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1600-6143.2011.03784.x","article-title":"The nature of biopsies with \u201cborderline rejection\u201d and prospects for eliminating this category.","volume":"12","author":"de Freitas","year":"2012","journal-title":"Am J Transplant"},{"key":"R2-20251023","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1111\/ajt.15860","article-title":"Evidence for the alloimmune basis and prognostic significance of borderline T cell-mediated rejection.","volume":"20","author":"Wiebe","year":"2020","journal-title":"Am J Transplant"},{"key":"R3-20251023","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1111\/ajt.15898","article-title":"The Banff 2019 Kidney Meeting Report (I): updates on and clarification of criteria for T cell- and antibody-mediated rejection.","volume":"20","author":"Loupy","year":"2020","journal-title":"Am J Transplant"},{"key":"R4-20251023","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/ajt.16093","article-title":"Significance of revised criteria for chronic active T cell-mediated rejection in the 2017 Banff classification: Surveillance by 1-year protocol biopsies for kidney transplantation.","volume":"21","author":"Nakagawa","year":"2021","journal-title":"Am J Transplant"},{"key":"R5-20251023","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1097\/TP.0000000000002366","article-title":"A 2018 reference guide to the Banff classification of renal allograft pathology.","volume":"102","author":"Roufosse","year":"2018","journal-title":"Transplantation"},{"key":"R6-20251023","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1681\/ASN.2014060588","article-title":"Disappearance of T cell-mediated rejection despite continued antibody-mediated rejection in late kidney transplant recipients.","volume":"26","author":"Halloran","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"R7-20251023","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1097\/TP.0000000000003838","article-title":"Correlation of donor-derived cell-free DNA with histology and molecular diagnoses of kidney transplant biopsies.","volume":"106","author":"Gupta","year":"2022","journal-title":"Transplantation"},{"key":"R8-20251023","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1681\/ASN.2021091191","article-title":"The Trifecta study: comparing plasma levels of donor-derived cell-free DNA with the molecular phenotype of kidney transplant biopsies.","volume":"33","author":"Halloran","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"R9-20251023","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/ajt.15752","article-title":"Discrepancy analysis comparing molecular and histology diagnoses in kidney transplant biopsies.","volume":"20","author":"Madill-Thomsen","year":"2020","journal-title":"Am J Transplant"},{"key":"R10-20251023","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1111\/ajt.15197","article-title":"The clinical and pathological significance of borderline T cell-mediated rejection.","volume":"19","author":"Nankivell","year":"2019","journal-title":"Am J Transplant"},{"key":"R11-20251023","doi-asserted-by":"crossref","first-page":"2054358117753616","DOI":"10.1177\/2054358117753616","article-title":"Practice patterns in the treatment and monitoring of acute T cell-mediated kidney graft rejection in Canada.","volume":"5","author":"Leblanc","year":"2018","journal-title":"Can J Kidney Health Dis"},{"key":"R12-20251023","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1111\/ajt.13784","article-title":"Banff borderline changes suspicious for acute T cell-mediated rejection: where do we stand?","volume":"16","author":"Becker","year":"2016","journal-title":"Am J Transplant"},{"key":"R13-20251023","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1111\/ajt.15351","article-title":"Generating automated kidney transplant biopsy reports combining molecular measurements with ensembles of machine learning classifiers.","volume":"19","author":"Reeve","year":"2019","journal-title":"Am J Transplant"},{"key":"R14-20251023","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/MOT.0000000000000193","article-title":"The molecular phenotypes of rejection in kidney transplant biopsies.","volume":"20","author":"Halloran","year":"2015","journal-title":"Curr Opin Organ Transplant"},{"key":"R15-20251023","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/nrneph.2016.85","article-title":"Molecular assessment of disease states in kidney transplant biopsy samples.","volume":"12","author":"Halloran","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"R16-20251023","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1111\/ajt.14329","article-title":"Real time central assessment of kidney transplant indication biopsies by microarrays: the INTERCOMEX study.","volume":"17","author":"Halloran","year":"2017","journal-title":"Am J Transplant"},{"key":"R17-20251023","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/ajt.14625","article-title":"The Banff 2017 Kidney Meeting Report: revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials.","volume":"18","author":"Haas","year":"2018","journal-title":"Am J Transplant"},{"key":"R18-20251023","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race.","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"R19-20251023","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.kint.2024.06.007","article-title":"Clinical trial designs to assess treatment effects on glomerular filtration rate decline.","volume":"106","author":"Heerspink","year":"2024","journal-title":"Kidney Int"},{"key":"R20-20251023","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1111\/ajt.15299","article-title":"Response to treatment and long-term outcomes in kidney transplant recipients with acute T cell-mediated rejection.","volume":"19","author":"Bouatou","year":"2019","journal-title":"Am J Transplant"},{"key":"R21-20251023","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/tri.13318","article-title":"Early allograft inflammation and scarring associate with graft dysfunction and poor outcomes in renal transplant recipients with delayed graft function: a prospective single center cohort study.","volume":"31","author":"Cherukuri","year":"2018","journal-title":"Transpl Int"},{"key":"R22-20251023","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1097\/TP.0000000000002560","article-title":"The impact of early clinical and subclinical T cell-mediated rejection after kidney transplantation.","volume":"103","author":"Hoffman","year":"2019","journal-title":"Transplantation"},{"key":"R23-20251023","doi-asserted-by":"crossref","first-page":"e706","DOI":"10.1097\/TXD.0000000000001132","article-title":"Impact of subclinical and clinical kidney allograft rejection within 1 year posttransplantation among compatible transplant with steroid withdrawal protocol.","volume":"7","author":"Owoyemi","year":"2021","journal-title":"Transplant Direct"},{"key":"R24-20251023","doi-asserted-by":"crossref","first-page":"e663","DOI":"10.1097\/TXD.0000000000001119","article-title":"Impact of subclinical borderline inflammation on kidney transplant outcomes.","volume":"7","author":"Seifert","year":"2021","journal-title":"Transplant Direct"},{"key":"R25-20251023","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.kint.2019.01.033","article-title":"Post-transplant donor specific antibody is associated with poor kidney transplant outcomes only when combined with both T-cell-mediated rejection and non-adherence.","volume":"96","author":"Cherukuri","year":"2019","journal-title":"Kidney Int"},{"key":"R26-20251023","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1097\/TP.0000000000000448","article-title":"De novo donor-specific human leukocyte antigen antibodies in nonsensitized kidney transplant recipients after T cell-mediated rejection.","volume":"99","author":"Chemouny","year":"2015","journal-title":"Transplantation"},{"key":"R27-20251023","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1111\/ajt.12370","article-title":"Kidney allograft survival after acute rejection, the value of follow-up biopsies.","volume":"13","author":"El Ters","year":"2013","journal-title":"Am J Transplant"},{"key":"R28-20251023","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1111\/ajt.15754","article-title":"Development and outcomes of de novo donor-specific antibodies in low, moderate, and high immunological risk kidney transplant recipients.","volume":"20","author":"Wan","year":"2020","journal-title":"Am J Transplant"},{"key":"R29-20251023","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1056\/NEJM200010053431407","article-title":"T-cell function and migration. Two sides of the same coin.","volume":"343","author":"von Andrian","year":"2000","journal-title":"N Engl J Med"},{"key":"R30-20251023","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1111\/ajt.15822","article-title":"High levels of dd-cfDNA identify patients with TCMR 1A and borderline allograft rejection at elevated risk of graft injury.","volume":"20","author":"Stites","year":"2020","journal-title":"Am J Transplant"},{"key":"R31-20251023","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/TP.0000000000004284","article-title":"The molecular diagnosis might be clinically useful in discrepant kidney allograft biopsy findings: an analysis of clinical outcomes.","volume":"107","author":"Schachtner","year":"2022","journal-title":"Transplantation"},{"key":"R32-20251023","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1111\/ajt.16161","article-title":"Factors associated with kidney graft survival in pure antibody-mediated rejection at the time of indication biopsy: importance of parenchymal injury but not disease activity elevated AT1R antibody and morbidity in patients bridged to heart transplant using continuous flow left ventricular assist devices impact of belatacept conversion on renal function, histology, and gene expression in kidney transplant patients with chronic active antibody-mediated rejection lack of histological and molecular signature response to tocilizumab in kidney transplants with chronic active antibody mediated rejection: a case series.","volume":"21","author":"Einecke","year":"2021","journal-title":"Am J Transplant"},{"key":"R33-20251023","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1097\/TP.0000000000004396","article-title":"Relating molecular T cell-mediated rejection activity in kidney transplant biopsies to time and to histologic tubulitis and atrophy-fibrosis.","volume":"107","author":"Madill-Thomsen","year":"2023","journal-title":"Transplantation"},{"key":"R34-20251023","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1681\/ASN.2011090887","article-title":"Molecular phenotypes of acute kidney injury in kidney transplants.","volume":"23","author":"Famulski","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"R35-20251023","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/ajt.12080","article-title":"Kidney transplants with progressing chronic diseases express high levels of acute kidney injury transcripts.","volume":"13","author":"Famulski","year":"2013","journal-title":"Am J Transplant"},{"key":"R36-20251023","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1111\/ajt.16161","article-title":"Factors associated with kidney graft survival in pure antibody-mediated rejection at the time of indication biopsy: importance of parenchymal injury but not disease activity.","volume":"21","author":"Einecke","year":"2021","journal-title":"Am J Transplant"},{"key":"R37-20251023","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1097\/TP.0000000000004396","article-title":"Relating molecular T cell- mediated rejection activity in kidney transplant biopsies to time and to histologic tubulitis and atrophy-fibrosis.","volume":"107","author":"Madill-Thomsen","year":"2023","journal-title":"Transplantation"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005296","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T11:00:35Z","timestamp":1761217235000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,23]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000005296","relation":{},"ISSN":["0041-1337","1534-6080"],"issn-type":[{"value":"0041-1337","type":"print"},{"value":"1534-6080","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,23]]}}}